NewAmsterdam Pharma Company NV (NAMS)
NASDAQ
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibit... NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Show more
NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
NAARDEN, The Netherlands and MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
NAARDEN, The Netherlands and MIAMI, July 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
-- New patent extends patent term for obicetrapib until July 2043 -- NAARDEN, the Netherlands and MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or...
NAARDEN, the Netherlands and MIAMI, June 07, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
NAARDEN, the Netherlands and MIAMI, May 29, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers -- -- On track to report topline...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 3.78 | 20.2030999466 | 18.71 | 19.51 | 18.52 | 81996 | 18.86852869 | CS |
| 4 | 3.09 | 15.9278350515 | 19.4 | 21.4358 | 18.15 | 217701 | 19.65672969 | CS |
| 12 | 0.79 | 3.64055299539 | 21.7 | 22.79 | 16.6201 | 170760 | 19.56694156 | CS |
| 26 | -2.01 | -8.20408163265 | 24.5 | 25.255 | 16.6201 | 201201 | 20.51145218 | CS |
| 52 | 11.08 | 97.1078001753 | 11.41 | 26.35 | 5.6326 | 168660 | 16.91307778 | CS |
| 156 | 11.49 | 104.454545455 | 11 | 32.88 | 5.6326 | 122871 | 16.11947508 | CS |
| 260 | 11.49 | 104.454545455 | 11 | 32.88 | 5.6326 | 122871 | 16.11947508 | CS |
Monksdream
4 months ago
makinezmoney
1 year ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
